SELLAS Life Sciences Group Statistics
Share Statistics
SELLAS Life Sciences Group has 70.38M shares outstanding. The number of shares has increased by 100.65% in one year.
| Shares Outstanding | 70.38M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 11.39% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 69.67M |
| Failed to Deliver (FTD) Shares | 771 |
| FTD / Avg. Volume | 0.09% |
Short Selling Information
The latest short interest is 8.61M, so 12.23% of the outstanding shares have been sold short.
| Short Interest | 8.61M |
| Short % of Shares Out | 12.23% |
| Short % of Float | 12.29% |
| Short Ratio (days to cover) | 14.07 |
Valuation Ratios
The PE ratio is -0.79 and the forward PE ratio is -3.05.
| PE Ratio | -0.79 |
| Forward PE | -3.05 |
| PS Ratio | 0 |
| Forward PS | 1.9 |
| PB Ratio | -3.69 |
| P/FCF Ratio | -0.8 |
| PEG Ratio | n/a |
Enterprise Valuation
SELLAS Life Sciences Group Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 0.23, with a Debt / Equity ratio of 0.
| Current Ratio | 0.23 |
| Quick Ratio | 0.23 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 4.68% and return on capital (ROIC) is 535.63%.
| Return on Equity (ROE) | 4.68% |
| Return on Assets (ROA) | -6% |
| Return on Capital (ROIC) | 535.63% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -2.33M |
| Employee Count | 16 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -23.48% in the last 52 weeks. The beta is 2.4, so SELLAS Life Sciences Group 's price volatility has been higher than the market average.
| Beta | 2.4 |
| 52-Week Price Change | -23.48% |
| 50-Day Moving Average | 1.19 |
| 200-Day Moving Average | 1.25 |
| Relative Strength Index (RSI) | 25.11 |
| Average Volume (20 Days) | 898.63K |
Income Statement
In the last 12 months, SELLAS Life Sciences Group had revenue of $0 and earned -$37.34M in profits. Earnings per share was $-1.34.
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -37.87M |
| Net Income | -37.34M |
| EBITDA | 529.00K |
| EBIT | - |
| Earnings Per Share (EPS) | -1.34 |
Balance Sheet
The company has $2.53M in cash and $906.00K in debt, giving a net cash position of $1.62M.
| Cash & Cash Equivalents | 2.53M |
| Total Debt | 906.00K |
| Net Cash | 1.62M |
| Retained Earnings | -217.24M |
| Total Assets | 26.50M |
| Working Capital | 13.42M |
Cash Flow
In the last 12 months, operating cash flow was -$31.41M and capital expenditures -$5.50M, giving a free cash flow of -$36.91M.
| Operating Cash Flow | -31.41M |
| Capital Expenditures | -5.50M |
| Free Cash Flow | -36.91M |
| FCF Per Share | -1.33 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
SLS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -152.27% |
| FCF Yield | -59.63% |
Analyst Forecast
The average price target for SLS is $3, which is 240.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $3 |
| Price Target Difference | 240.9% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Nov 8, 2019. It was a backward split with a ratio of 1:50.
| Last Split Date | Nov 8, 2019 |
| Split Type | backward |
| Split Ratio | 1:50 |
Scores
| Altman Z-Score | -12.8 |
| Piotroski F-Score | 2 |